Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04836832
Status:
WITHDRAWN
Last Update Posted:
2022-06-07
First Post:
2021-03-09
Brief Title:
Acalabrutinib and Duvelisib for the Treatment of RelapsedRefractory Indolent Non-Hodgkin Lymphoma
Sponsor:
Narendranath Epperla
Organization:
Ohio State University Comprehensive Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Refractory Splenic Marginal Zone Lymphoma |
| Recurrent Follicular Lymphoma |
| Recurrent Marginal Zone Lymphoma |
| Recurrent Nodal Marginal Zone Lymphoma |
| Recurrent Splenic Marginal Zone Lymphoma |
| Refractory Follicular Lymphoma |
| Refractory Indolent Non-Hodgkin Lymphoma |
| Refractory Marginal Zone Lymphoma |
| Refractory Nodal Marginal Zone Lymphoma |
Keywords: